Literature DB >> 1732075

Interethnic difference in thiopurine methyltransferase activity.

B Klemetsdal1, E Tollefsen, T Loennechen, K Johnsen, E Utsi, K Gisholt, E Wist, J Aarbakke.   

Abstract

A number of metabolic pathways are subject to both genetic polymorphism and interethnic differences. A catabolic pathway of 6-mercaptopurine, red blood cell (RBC) thiopurine methyltransferase (TPMT) activity showed genetic polymorphism in Caucasians, but variation according to ethnicity has not been studied. We investigated if red blood cell thiopurine methyltransferase was subject to interethnic variation in a Saami (Lappish; n = 36) and a Caucasian population (n = 50). The Saami population sample had 29% higher thiopurine methyltransferase activity, 17.0 +/- 3.3 U/ml red blood cell compared with the Caucasian population sample, 13.1 +/- 2.9 U/ml red blood cell (p much less than 0.001). Probit plots and frequency distribution histograms supported bimodality consistent with genetic polymorphism in both study populations. Differences in chronic diseases, drug consumption, age, or gender could not explain the interethnic difference in red blood cell thiopurine methyltransferase activity. The higher red blood cell thiopurine methyltransferase activity in the Saami population group indicates that these subjects may require higher dosages of thiopurine drugs than Caucasians.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732075     DOI: 10.1038/clpt.1992.4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Pharmacogenomics in pediatric leukemia.

Authors:  Steven W Paugh; Gabriele Stocco; William E Evans
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 2.  How important are gender differences in pharmacokinetics?

Authors:  Bernd Meibohm; Ingrid Beierle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Human thiopurine methyltransferase activity varies with red blood cell age.

Authors:  L Lennard; T S Chew; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

4.  Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups.

Authors:  Jian-ping Zhang; Yong-yuan Guan; Jue-heng Wu; An-long Xu; Shufeng Zhou; Min Huang
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

5.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 6.  Practical treatment guide for dose individualisation in cancer chemotherapy.

Authors:  P Canal; E Chatelut; S Guichard
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

7.  Erythrocyte fraction affects red blood cell thiopurine methyltransferase activity.

Authors:  B Klemetsdal; B Straume; R Lysaa; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population.

Authors:  B Klemetsdal; B Straume; E Wist; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors.

Authors:  E Jacqz-Aigrain; E Bessa; Y Medard; Y Mircheva; E Vilmer
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

10.  Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression.

Authors:  Malin Lindqvist; Sven Almer; Curt Peterson; Peter Söderkvist
Journal:  Eur J Clin Pharmacol       Date:  2003-06-19       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.